Diabetes melitus

The therapeutic application of this drug is limited to such subjects having a history of stable, mild to mderately severe diabetes melitus who still retain residual pancreatic 3-cell function to a certain extent. 

It is mostly beneficial in the treatment of selected cases of non-insulin-dependent diabetes melitus (NIDDM). Interestingly, only such patients having some residual functional islet P-cells which may be stimulated by this drug shall afibrd a positive response. Therefore, it is quite obvious that such subjects who essentially need more than 40 Units of insulin per day normally will not respond to this drug. 

It is mostly used for Type 2 diabetes melitus. It is found to be almost 200 times as potent as tolbutamide in evoking the release of insulin from the pancreatie islets. However, it exerts a rather more effeetive agent in causing suppression offasting than postprandial hypeiglycemia. 

Excess of potassium in the body dam2iges the tissues of the body and muscles are contracted violently. It also increases ATPase and kinase activity with the loss of sodium ions. Hyperkalemia is foimd in patients suffering from (i) Addison s disease (ii) diabetes melitus (iii) renal failure (iv) severe dehydration. 

---